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Abstract: Bariatric surgery is currently the most effective option for the treatment of morbid 
obesity and its associated comorbidities. Recent clinical and experimental findings have chal-
lenged the role of mechanical restriction and caloric malabsorption as the main mechanisms 
for weight loss and health benefits. Instead, other mechanisms including increased levels of 
satiety gut hormones, altered gut microbiota, changes in bile acid metabolism, and/or energy 
expenditure have been proposed as explanations for benefits of bariatric surgery. Beside the 
standard proximal Roux-en-Y gastric bypass and the biliopancreatic diversion with or without 
duodenal switch, where parts of the small intestine are excluded from contact with nutrients, 
resectional techniques like the sleeve gastrectomy (SG) have recently been added to the armory 
of bariatric surgeons. The variation of weight loss and glycemic control is vast between but also 
within different bariatric operations. We surveyed members of the Swiss Society for the Study 
of Morbid Obesity and Metabolic Disorders to assess the extent to which the phenotype of 
patients influences the choice of bariatric procedure. Swiss bariatric surgeons preferred Roux-
en-Y gastric bypass and SG for patients with type 2 diabetes mellitus and patients with a body 
mass index >50 kg/m2, which is consistent with the literature. An SG was preferred in patients 
with a high anesthetic risk or previous laparotomy. The surgeons’ own experience was a major 
determinant as there is little evidence in the literature for this approach. Although trends will 
come and go, evidence-based medicine requires a rigorous examination of the proof to inform 
clinical practice.
Keywords: bariatric procedures, underlying physiology, choice of type of surgery
Introduction
Previously, it was thought that caloric malabsorption and food restriction were 
important mechanisms determining the outcome of bariatric surgery. However, both 
preclinical and clinical studies revealed that complex physi logical changes lead 
to body weight loss and beneficial metabolic changes after bariatric surgeries, such 
as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). Mechanisms 
include altered levels of satiety gut hormones,1,2 alterations in energy expenditure,3–7 
changes in bile acid levels,8–11 and modified gut microbiota.12–14 “Association” should, 
however, not be confused with “causation” as the measurable changes in circulat-
ing parameters after bariatric surgery do not necessarily infer a causal relationship 
with the benefits of surgery. It remains unclear whether these mechanisms alone or 
in combination with others are necessary or sufficient for reduced food intake or 
body weight loss.
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There are substantial variations as regards metabolic 
efficacy between and within different surgical techniques, 
which can complicate clinical decision-making. This review 
focusses on the most common bariatric procedures and sum-
marizes potential underlying physiological mechanisms. 
Moreover, we will report on a survey among clinicians in 
Switzerland as to which surgical technique they prefer in 
different scenarios. The findings are then presented within 
the framework of currently available evidence.
Common bariatric surgical 
techniques
Currently, RYGB and SG are the most commonly performed 
bariatric surgeries worldwide.15 Gastric banding (GB) has 
lost a lot of its popularity within the last 10 years, whereas 
biliopancreatic diversion with or without duodenal switch 
remains the operation of choice in only a few international 
centers.15 The latter two procedures will therefore not be 
discussed in detail in this review.
Currently, bariatric procedures are almost always per-
formed laparoscopically.15 For the RYGB, the stomach is 
divided into a proximal gastric pouch with a volume of 
about 15–30 mL and a distal gastric remnant (please see for 
preoperative anatomy Figure 1A). Similarly, the jejunum 
is transected approximately 50 cm distal to the ligament 
of Treitz, creating a proximal and distal end of jejunum. 
An anastomosis between the distal end of the jejunum and 
the gastric pouch (gastrojejunostomy) creates the so-called 
alimentary limb. The proximal end of the jejunum, still 
 continuous with the gastric remnant, constitutes the so-called 
biliopancreatic limb and is anastomosed with the small bowel 
approximately 150 cm distal from gastrojejunostomy leading 
to formation of the common channel. Thus, after comple-
tion of the standard Roux-en-Y reconstruction, there is an 
alimentary limb of 100–150 cm, a biliopancreatic limb of 
50 cm, and a common channel of variable length, typically 
300–500 cm (Figure 1B).16
For the SG, the stomach is stapled along the big curvature 
creating a gastric tube of a volume of around 100–200 mL 
leading to an accelerated gastric emptying (Figure 1C).17
Underlying physiological 
mechanisms of bariatric surgery
For decades, the body-weight-lowering effects of bariatric 
procedures were mainly attributed to mechanical restriction 
and caloric malabsorption. However, an increasing body of 
evidence questions the contribution of these anatomical and 
mechanical explanations. Recent findings suggest the impor-
tance of physiological mechanisms including changes in gas-
trointestinal hormone levels,1,2,18,19 bile acid  metabolism,8–11 
gut microbiota,13,14,20,21 and energy expenditure,3–7 among 
others. Key findings pertaining to these mechanisms will be 
briefly introduced with a special focus on the RYGB proce-
dure, which is the most commonly performed and studied 
bariatric surgery worldwide. When possible and appropriate, 
reference will also be made to the SG.
Figure 1 Schematic illustration of the preoperative (A) and postoperative anatomy of the gastrointestinal tract after a Roux-en-Y gastric bypass (B), and sleeve 
gastrectomy (C).
Note: Reproduced from Lutz T, Bueter M. Wohin geht die Anti-Obesitas Therapie? Prakt Tierarzt. 2012;93(12):1087–1095.95
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Changes in gut hormones
The most consistent findings after RYGB in patients and 
animal models of RYGB are the increased secretion of satiety 
gut hormones after RYGB surgery.1,2,18,19,22,23 Several studies 
focused on altered levels of gut hormones that are known to 
affect food intake and to modulate nutrient metabolism.24–26 
Insights into the role of gut hormones in the control of eating 
behavior has led to their therapeutic exploitation as possible 
antiobesity drugs.27
Glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) 
responses are elevated postprandially after RYGB and 
SG.2,26,28–30 Circulating GLP-1 and PYY are released by the 
enteroendocrine L-cells when in direct contact with nutrients 
or bile acids in the gastrointestinal tract.31,32 When RYGB 
patients are divided into “good and poor responders”, those 
with more weight loss had significantly higher postprandial 
GLP-1 and PYY responses.33 To examine causation of the 
elevated gut hormone response, blockade of these responses 
with somatostatin analogs resulted in increased food intake in 
three groups, including RYGB patients, rats after RYGB, and 
patients after esophagectomy with gastric conduit reconstruc-
tion (which mimics SG in both anatomy and physiology).2,34,35 
However, although blockade of all postprandial gut hormones 
led to doubling of food intake, the amount of calories con-
sumed was still lower than preoperative values, suggesting 
that other mechanisms may also play an important role.2,36
The underlying mechanisms of an increase in postprandial 
GLP-1 and PYY L-cell secretion after RYGB surgery remain 
controversial. One explanation is the exposure of the distal 
gut lumen to higher concentrations of undigested nutrients 
as distal parts of the small intestine exhibit a higher mucosal 
L-cell density.37–39 Alternatively, increased L-cell secretions 
may also be due to enhanced stimulation of L-cells by bile 
acids or even gut microbial interactions.31,32
However, measurable changes in circulating parameters 
after bariatric surgery do not necessarily mean that these 
hormones have a causal role.40 In other words, it is not yet 
clear whether hormonal changes alone or in combination with 
other mechanisms are necessary or sufficient for reduced food 
intake or body weight. Most efforts trying to establish a causal 
role for single hormones in RYGB-mediated effects have 
failed so far. For example, inhibition of a single gut hormone 
appears insufficient as the efficacy of RYGB is unaffected in 
GLP-1 receptor-knockout mice.41 Moreover, central blockade 
of GLP-1 receptors as well as blockade of PYY receptors 
also did not affect food intake in either sham-operated or 
RYGB-operated rats.41 Thus, there remains a certain level 
of uncertainty regarding the causal role of gut hormones 
for the observed changes in eating behavior after bariatric 
surgery, and it becomes evident that many different – partly 
unknown – factors may underlie the effects of RYGB surgery.
Bile acids
Levels of systemic bile acid concentrations are decreased 
in obese individuals.42 Bile acids act through various recep-
tors, including the FXR and the TGR5, to influence nutrient 
metabolism and energy expenditure. RYGB normalizes 
postprandial plasma bile acid responses,42 whereas systemic 
bile acid levels increase massively and may therefore be 
responsible for some RYGB-induced effects.8–10,43 Increased 
bile acids may also explain the increased secretion of GLP-1 
and PYY after RYGB via TGR5 receptors located in the 
luminal membrane of L-cells.44 However, TGR5 stimula-
tion would require a higher bile acid concentration in the 
intestinal lumen, which has not yet been shown.45 A causal 
contribution of bile acids to increased L-cell secretion after 
RYGB has also not yet been tested, and specific antagonists 
of TGR5 are currently not available. Experiments with TGR5 
knockout mice undergoing RYGB are still awaited.
As bile acids increase energy expenditure in skeletal 
muscle and in brown adipose tissue,46 and because circulating 
bile acids are strongly correlated with postprandial energy 
expenditure in lean individuals,47 altered bile acid levels may 
contribute to changes in postprandial energy expenditure 
after RYGB.
In SG-operated mice, bile acid signaling via the FXR has 
been suggested to be a key determinant of body weight loss 
and glucose homeostasis.11 So far, similar studies have not 
yet been performed after RYGB.
Gut microbiota
Numerous studies in recent years have shown that metabolic 
processes mediated by the gut microbiome play an important 
role in whole-body metabolism in health and disease.12–14,48–50 
The observation that fecal transfer of gut microbiota from 
obese donors can induce body weight gain in lean recipients 
has led to intensive research activities in recent years to 
investigate the role of the gut microbiome on the observed 
metabolic effects after bariatric surgery.50 Changes in gut 
microbiota seem to directly contribute to reduced body 
weight and obesity after RYGB as transfer of gut microbiota 
from RYGB-treated mice to nonoperated, germ-free mice 
resulted in body weight loss and decreased fat mass in the 
recipient animals.13 In humans, variations of gut microbiota 
after RYGB are associated with changes in the expression of 
various genes in white adipose tissue, indicating a direct link 
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between these two processes.21,51,52 Furthermore, postbariatric 
changes of the gut microbiome occur independently of body 
mass index (BMI) and result in altered levels of fecal and 
circulating metabolites compared with obese controls.14 By 
colonizing germ-free mice with stools from the patients, the 
RYGB-altered microbiota promoted reduced fat deposition 
in recipient mice.14
An interaction between the gut microbiota and bile acid 
metabolism is probable as bile acids have known antibacte-
rial effects. In addition, gut microbiota is known to be able 
to chemically modify endogenous bile acids to a number of 
different chemical species with different affinities at different 
bile acid receptors.53
Energy expenditure
Changes in energy expenditure after RYGB in humans are 
controversial.6,7,54,55 Thivel et al56 recently reviewed the avail-
able data on energy expenditure after bariatric surgery and 
concluded that the total energy expenditure in humans often 
decreases postoperatively due to the decrease in fat-free and 
fat mass, but that postprandial diet-induced thermogenesis 
is often increased. A few human studies suggest an increase 
in total energy expenditure after RYGB.6,7 Discrepancy in 
findings may be explained by the short duration of energy 
expenditure measurements and by the subsequent extrapola-
tion of results to a 24-hour period; hence, true effects may 
have been missed. The necessary control groups were also 
not always included in the studies.
Compared to the human studies, data in rats and mice are 
more consistent, where RYGB seems to prevent or at least 
reduce the usual adaptive response (also known as “starvation 
response”), ie, body weight loss in RYGB rats is not associ-
ated with the same decrease in reduced energy expenditure 
that parallels weight loss by food restriction.3–5
RYGB and SG often produce similar changes in metabo-
lism,57,58 but data indicate that changes in energy expenditure 
may not be an important contributor to body weight loss 
after SG.59,60 Furthermore, both clinical and animal studies 
have reported at least regain of body weight after SG, which 
could be explained by differences in postoperative energy 
expenditure between RYGB and SG.60,61
The physiological mechanisms underlying altered energy 
expenditure after RYGB are only incompletely understood, 
although it seems evident that neither an increased spontane-
ous physical activity nor a general increase in body tempera-
ture due to postoperative inflammation plays a role.3 Instead, 
potential mechanisms include changes in gut hormone lev-
els,3 altered brown adipose tissue activity,62 altered energy 
efficiency of skeletal muscle, or a higher energy requirement 
of hypertrophied small intestine.3,4,31,32,63
Survey
Surgical and nonsurgical members (n=177) of the Swiss 
Society for the Study of Morbid Obesity and Metabolic Dis-
orders representing 52 bariatric centers in Switzerland were 
formally invited by email to participate in the survey and to 
complete a nonvalidated, self-designed questionnaire. All 
responses that were received within 3 weeks after the initial 
contact were included in the analysis. In the questionnaire, 
participants were asked to indicate which of the following 
clinical conditions impacts their surgical treatment of choice 
to which degree (0 – no impact, 1 – minor impact, 3 – major 
impact):
1. Difficult to treat type 2 diabetes mellitus (T2DM), eg, 
high dosages of insulin or high HbA1c levels
2. BMI >50 kg/m2
3. Concomitant hiatal herniation
4. Open abdominal surgery in patients’ previous medical 
history
5. Increased anesthetic risk, ie, American Society of Anes-
thesiologists (ASA) >III.
If the impact of these conditions was considered to be either 
minor or major, participants were further asked to indicate their 
preferred surgical technique in this situation (GB, SG, RYGB, 
or biliopancreatic diversion [BPD]). Responses favoring more 
than one operation were possible. The questionnaire was com-
pleted by 24 participants representing 24 different centers of 
bariatric surgery in Switzerland. The responses were obtained 
from 13.6% of Study of Morbid Obesity and Metabolic Disor-
ders members and 46% of all Swiss bariatric centers.
About 79% of participants regarded the presence of 
severe T2DM as major and 21% as minor importance for 
their choice of surgical technique. Of these, the majority 
reported a preference for RYGB (n=20) over a BPD (n=12) 
or SG (n=7). None of the participants indicated GB as the 
operation of choice in this situation. A BMI >50 kg/m2 was 
considered to be of major importance by 66% of participants, 
whereas 33% regarded it as being of minor importance. In this 
situation, the majority of participants reported that they prefer 
an SG as their first option (n=19) over an RYGB (n=10) or 
a BPD (n=9). Again, none of the participants suggested GB.
In total, 33% participants reported that the presence of 
a hiatal hernia has major impact on their choice of surgical 
technique, whereas 58% consider the presence of hiatal 
 herniation as less important and 8% as not important at all 
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for their decision. Of these, the majority of responders con-
sidered an RYGB as their preferred option (n=18), whereas 
only five and three participants, respectively, consider an SG 
or BPD in this situation. None of the participants considered 
a GB for patients with hiatal herniation.
Previous open abdominal surgery was regarded to be of 
minor importance for decision-making by 63% of partici-
pants, whereas 33% attach no impact and 4% attach major 
impact to this clinical condition. However, the majority of 
responders preferred an SG (n=16), whereas eight partici-
pants considered an RYGB and only one participant a BPD 
as potential options. In addition, two colleagues considered 
a GB as a potential option.
Finally, an increased anesthetic risk indicated by an ASA 
score >III was given major importance by 42% and minor 
importance by 46% of the participants. Interestingly, 13% of 
the participants consider anesthetic risk as not important at 
all. In patients with increased anesthetic risk (ASA >III), most 
participants chose SG (n=16), whereas fewer participants 
considered an RYGB (n=8), a GB (n=2), or a BPD operation 
(n=1) as the preferred option.
Current evidence to support results 
of the survey
Type 2 diabetes mellitus
Bariatric surgery has been shown to induce and maintain 
normoglycemia in obese patients suffering from T2DM 
more effectively than any present medical therapy alone for 
5 years.64–67 The results obtained from our survey suggest that 
bariatric surgeons consider severe T2DM as an important 
factor when it comes to the choice of bariatric procedure. 
However, the question of whether one single bariatric pro-
cedure is superior to all other procedures in patients with 
T2DM is challenging as many factors need to be considered.
The best evidence for T2DM remission is available for 
RYGB and SG. In the study of Schauer et al,66,67 both bariatric 
surgeries improved glycemic control; however, the number of 
patients with normal HbA1c without antidiabetic medication 
was significantly higher 3 years after RYGB than after SG (28 
vs 16, P>0.01).66 RYGB was also more effective than SG in 
terms of HbA1c reduction and partial remission of T2DM.68 
Other randomized controlled trials showed glycemic control 
to a similar extent for both surgical procedures.57,69–73
Jimenez et al74 performed continuous glucose monitoring 
after ingestion of a standardized liquid mixed meal. They 
observed an earlier and higher peak of serum glucose levels 
in RYGB patients. Moreover, RYGB patients spent more 
time in a hypoglycemic state than patients after SG.74 Both 
high glucose peaks as well as the fast changes from hyper- to 
hypoglycemic state are considered undesirable, as such an 
abnormal postprandial glucose profile may be associated 
with higher rates of relapse of diabetes over time. However, 
this has not been shown so far. In contrast, recent data sug-
gest that relapse of diabetes might be higher after SG than 
after RYGB.66
Interestingly, 50% of all bariatric surgeons in our sur-
vey considered BPD in case of severe metabolic disorder. 
However, BPD is only performed by a few surgeons due to 
an increased risk for surgical complications and long-term 
side effects such as diarrhea or micronutrient deficien-
cies.75 Although the study of Mingrone et al65 was primarily 
designed to compare medical with surgical treatment, it 
revealed that the remission rate of T2DM was higher and 
that relapse of hyperglycemia was lower 5 years after BPD 
than after RYGB.65
In contrast to RYGB and SG, GB has lost much of its 
initial attraction, although a randomized controlled trial by 
Dixon et al76 showed that 73% of recently diagnosed patients 
with T2DM achieve diabetic remission 2 years after their 
GB operation.
In summary, the evidence that bariatric surgery alone 
or in combination with best medical care is superior for the 
treatment of T2DM when compared to best medical care 
alone is undisputed.77 RYGB and SG seem to offer the best 
risk–benefit ratio, as other procedures such as BPD and GB 
are characterized in some setting by high complication rates 
and/or high numbers of reoperations.30
Severe obesity
Morbidly obese patients loose more weight after RYGB and 
SG operations than after laparoscopic adjustable GB, irre-
spective of their initial BMI.78–81 A multivariate regression 
analysis of the Bariatric Outcomes Longitudinal Database 
including 31 443 laparoscopic adjustable GB, 40 352 RYGB, 
and 2 194 SG patients demonstrated that the type of bariat-
ric surgery is the most important predictor of postoperative 
weight loss. Weight loss was highest after RYGB across all 
levels of body weight and significantly lower after GB. SG 
was underrepresented in this study, and thus comparison 
with RYGB was not possible.78 BPD was also not included 
in this analysis.
A systematic review including studies with >100 patients 
published before 2005 revealed that banded RYGB, a modifi-
cation of RYGB with placement of a nonadjustable or adjust-
able band around the gastric pouch, and BPD showed the best 
results in terms of weight loss 3 years after surgery. The lack 
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of long-term follow-up data and data of SG are important 
limitations of this study.82
SG, RYGB, and BPD are more effective in inducing and 
maintaining weight loss in patients with BMI >50 kg/m2, 
which is consistent with the results of our survey. Despite the 
fact that the existing evidence suggests a greater body weight 
loss after RYGB than after SG, the majority of bariatric 
surgeons in our survey favored SG for superobese patients, 
possibly because of technical considerations. The creation 
of gastrojejunostomy, which has to be performed for RYGB, 
can be challenging in this subgroup due to a large left liver 
lobe83,84 or accentuated visceral fat.85 Moreover, an SG can 
still be converted into an RYGB, if primary weight loss is 
insufficient or weight regain occurs.83 However, surgeons 
seem to place more importance on perceived safety and 
the avoidance of possible postsurgical side effects as one 
important guiding factor for the choice of the procedures.
Concomitant hiatal hernia
The prevalence of gastroesophageal reflux disease (GERD) 
in patients with morbid obesity is as high as 45%.86 GERD 
in morbidly obese patients is often associated or explained 
by the presence of a hiatal hernia.87 Hiatal hernias can be 
expected in up to 38.5% of patients undergoing bariatric 
surgery.88 The effect of different bariatric procedures on the 
resolution of GERD was investigated by Pallati et al,89 who 
found that the Savary–Miller GERD score improved after 
all procedures, with the best results being obtained after 
RYGB (56% of patients) when compared to GB (46%) and 
SG (41%). GERD symptoms in some SG patients deterio-
rated, whereas RYGB and Nissen fundoplication were found 
to be equally effective for the treatment of GERD in obese 
patients with hiatal hernia.90 Nearly all the participants of 
our survey considered hiatal hernia before deciding on the 
surgical technique.
Previous laparotomy
As every previous laparotomy increases the risk and extent 
of intra-abdominal adhesions,91 the technical difficulty and 
subsequent risk for complications of a laparoscopic approach 
may increase, too. However, the way this influences the sur-
geons’ choice has never been formally investigated in the con-
text of bariatric surgery. A retrospective study of 139 patients 
who underwent laparoscopy-assisted gastrectomy for early 
gastric cancer demonstrated that history of laparotomy was 
not associated with increased postoperative complications.92 
However, 80% of these previous laparotomies were due to 
appendectomies and gynecological operations. Moreover, 
operations were performed in a lean population; thus, the 
results may not be representative for a bariatric population 
where surgery is mainly limited to the upper gastrointestinal 
tract.
Our survey showed that a history of previous laparotomies 
impacts on the choice of bariatric procedure, although it was 
regarded only as a minor factor. The majority of participating 
surgeons favored SG, when faced with (several) previous 
laparotomies, probably intending to avoid complex adhe-
siolysis of the lower abdomen, which might be necessary for 
the lower anastomosis in case of RYGB or BPD.
Increased anesthesiological risk (ASA >III)
ASA class ≥III is an independent predictor of postoperative 
complications after RYGB.93,94 Interestingly, postoperative 
pulmonary complications differ significantly between RYGB 
(1.3%), SG (0.84%), and GB (0.3%), which may reflect dif-
ferences in the duration of surgery.94
The majority of participants of our survey consider a 
high anesthetic risk when they decide on the type of bariatric 
surgery. The majority of surgeons tend to prefer SG when the 
ASA score is >III whereas a small group of surgeons opted 
for GB in this situation. Differences may be explained by the 
intention to reduce operation time, which may be shorter for 
SG than RYGB,94 and also to reduce the risk for postopera-
tive anastomotic complications. Of course, operation time 
for GB is the shortest.94
Conclusion
Metabolic surgery is currently the most effective treatment 
for morbid obesity and its concomitant diseases. The armory 
should include RYGB, SG, BPD, and GB. Traditionally, the 
effects of bariatric surgery were explained by caloric mal-
absorption and mechanical restriction. However, animal and 
human studies challenged these mechanical explanations. 
Instead, other physiological mechanisms seem to be at play, 
such as alterations in gut hormone levels, changes in bile 
acid concentration, an altered composition of gut microbiota, 
as well as changes in energy expenditure. All these seem to 
contribute to the beneficial effects of bariatric surgery. The 
different effects of surgical procedures on body weight and 
comorbidities such as T2DM may be explained by the specific 
mechanisms of these operations, but more work is required 
to fully understand each contribution.
A survey among Swiss surgeons and clinical practitioners 
revealed that T2DM and BMI are major criteria considered 
during the choice of bariatric surgeries. In case of T2DM, 
most of the participants prefer RYGB over BPD as it has fewer 
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side effects, such as hypoproteinemia and diarrhea, although 
offering preferable improvements in terms of glycemic 
control. While T2DM remission rate seems slightly higher 
after RYGB, the smaller glucose excursions after food intake 
after SG may have benefits. Similarly, in case of a BMI >50 
kg/m2, the risk–benefit ratio seems best for SG and RYGB. 
Technical considerations like a large left liver lobe and the 
option of a later conversion to RYGB may be considered as 
reasons to rather perform a SG. Surgeons seem to prioritize 
perceived safety and avoidance of postsurgical side effects 
before selecting the procedure.
The presence of GERD should encourage surgeons 
to  perform RYGB because of its beneficial and weight- 
independent effects on GERD. Most participants of the 
survey prefer SG in cases of high anesthetic risk (ASA >III) 
and previous laparotomy in the patients’ history. In summary, 
choice of surgical procedure can be challenging as several 
competing factor requires consideration. Although consensus 
is emerging, no clear decision tree has been established as 
the underlying evidence is still lacking.
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